The present invention relates to the use of aptamer sensors.
This section is intended to introduce the reader to various aspects of art that may be related to various aspects of the present invention, which are described and/or claimed below. This discussion is believed to be helpful in providing the reader with background information to facilitate a better understanding of various aspects of the present invention. Accordingly, it should be understood that these statements are to be read in this light, and not as admissions of prior art.
Aptamers are nucleic acid or peptide molecules that bind to a target molecule with high specificity. After selection and enrichment, aptamers possess similar affinities to antibody-antigen pairs, but have the advantage of being able to be synthesized using standard methods. As synthetic molecules, aptamers also have unique advantages in the control of their size and their amenability for chemical modification and, as such, have been widely developed and applied in the development of sensors. Electrochemical, aptamer-based (EAB) sensors have emerged in recent years as a platform to detect proteins, small molecules, and inorganic ions, relying on the induced conformational change of oligonucleotide aptamers in the presence of specific analyte. When a target molecule binds to an aptamer, which may be tethered to an electrode surface, changes in the aptamer structure are measured by changes in the electrochemical signal of an attached redox label on the aptamer. EAB sensor technology presents a stable, reliable, bioelectric sensor that is sensitive to the target analyte in a sample, while being capable of multiple analyte capture events during the sensor lifespan.
At least one application of EAB sensors is continuous biosensing. While continuous biosensing has seen success primarily with glucose monitoring for diabetes, there has been little success beyond such applications. One of the fundamental challenges facing continuous biosensors is lifetime of the sensors, for which glucose-oxidase electrodes, an enzymatic electrode sensor, can currently provide up to 2 weeks of operation. In such glucose oxidase electrodes, these electrode surfaces need to be simply close to the electrically interrogating electrochemical electrode. However, that surface may change, for example by the presence of a fouling species, over time and the device will still operate. The challenge with glucose and other enzymatic sensors is that they are not generalizable. That is, unlike aptamers which are developed rapidly for a target analyte using SELEX technology, enzymes used in enzymatic sensors are not easily developed for any target analyte.
In contrast to enzymatic sensors, aptamer sensors are an emerging class of sensors that are highly generalizable, but they have their own drawbacks. The only truly continuous aptamer based sensors are those based on attachment of aptamers to an electrochemical electrode, which brings about lifetime challenges as the surface of that electrode is subject to degradation and fouling over time. Others have shown continuous use of ‘molecular beacon’ aptamers that are optical based, but these may not be suitable for continuous use for biosensing applications because they are conducted, for example, in a Petri dish. Such an example is not really a biosensor. Rather, such an arrangement is akin to a human having optical aptamers continuously injected into their blood and then fluorescently measured in-vivo. Rather, optical aptamers, to date, have not been included in any sensing device; instead, they are known only to have use as a stand-alone material, used in, for example, benchtop assay tests. This is unfortunate, because optical aptamer sensors could potentially have lifetimes that extend far beyond the current alternative sensor lifetimes because aptamer sensors need not be placed on an electrode surface. Therefore, a need still exists for devices that fully enable continuous sensing with optical aptamers.
Certain exemplary aspects of the invention are set forth below. It should be understood that these aspects are presented merely to provide the reader with a brief summary of certain forms the invention might take and that these aspects are not intended to limit the scope of the invention. Indeed, the invention may encompass a variety of aspects that may not be explicitly set forth below.
Many of the drawbacks and limitations stated above can be resolved by creating novel and advanced interplays of chemicals, materials, sensors, electronics, microfluidics, algorithms, computing, software, systems, and other features or designs, in a manner that affordably, effectively, conveniently, intelligently, or reliably brings sensing technology into proximity with sample fluids containing at least one analyte of interest to be measured.
Various aspects of the disclosed invention are directed to continuous aptamer sensors with previously unachievable performance by placing the aptamer in the solution phase with an architecture for the aptamer, and with cleaning strategies for electrodes that would otherwise foul or fully-passivate over long usage periods.
One particular aspect is directed to a continuous sensing device for sensing at least one analyte from a sample fluid is provided. The device includes a sensor fluid and a plurality of aptamers disposed in the sensor fluid. One or more aptamers of the plurality of aptamers is configured to bind to an analyte. Each of the aptamers includes at least one optical tag, and the optical tag is configured to provide a change in at least one optical property between a first state in which the aptamer is bound to the analyte and a second state in which the aptamer is not bound to the analyte. The shape of the aptamer differs in first state and the second state. The device further includes at least one isolation element retaining the aptamer in the sensor fluid, an optical source configured to emit light, the optical source in communication with the sensor fluid, and an optical detector configured to detect a change in at least one optical property of the aptamers.
Another particular aspect is directed to a method of sensing an analyte in a sample solution is also provided. The method includes bringing a sample fluid into contact with a plurality of aptamers in a sensor fluid. One or more aptamers of the plurality of aptamers includes a fluorescent tag and a quencher. The fluorescent tag is configured to emit an amount of light, and the quencher is configured to quench at least a portion of the light emitted by the fluorescent tag, the aptamer is configured to shift between an open state in which the aptamer is bound to the analyte and a closed state in which the aptamer is not bound to the analyte. Furthermore, the aptamer configured to emit more light in the open state than in the closed state. The method further includes binding the analyte included in the sample solution to the aptamer resulting in an increase in fluorescence emitted by the aptamer. The method further includes detecting the increased fluorescence emitted by the aptamer.
The objects and advantages of the disclosed invention will be further appreciated in light of the following detailed descriptions and drawings in which:
As used herein, “continuous sensing” with a “continuous sensor” means a sensor that changes in response to changing concentration of at least one solute in a solution such as an analyte. Similarly, as used herein, “continuous monitoring” means the capability of a device to provide multiple measurements of an analyte over time.
As used herein, the term “about,” when referring to a value or to an amount of mass, weight, time, volume, pH, size, concentration or percentage is meant to encompass variations of in some embodiments ±20%, in some embodiments ±10%, in some embodiments ±5%, in some embodiments ±1%, in some embodiments ±0.5%, and in some embodiments ±0.1% from the specified amount, as such variations are appropriate to perform the disclosed method.
As used herein, the term “aptamer” means a molecule that undergoes a conformation or binding change as an analyte binds to the molecule, and which satisfies the general operating principles of the sensing method as described herein. Such molecules are, e.g., natural or modified DNA, RNA, or XNA oligonucleotide sequences, spiegelmers, peptide aptamers, and affimers. Modifications may include substituting unnatural nucleic acid bases for natural bases within the aptamer sequence, replacing natural sequences with unnatural sequences, or other suitable modifications that improve sensor function but which behave analogous to traditional aptamers. Two or more aptamers bound together can also be referred to as an aptamer (i.e. not separated in solution). Aptamers can have molecular weights of at least 1 kDa, 10 kDa, or 100 kDa.
As used herein, the term “change in electron transfer” means a redox tag whose electron transfer with an electrode has changed in a measurable manner. This change in electron transfer can, for example, originate from availability for electron transfer, distance from an electrode, diffusion rate to or from an electrode, a shift or increase or decrease in electrochemical activity of the redox tag, or any other embodiment as taught herein that results in a measurable change in electron transfer between the redox tag and the electrode.
As used herein, the term “fluorescent tag”, “tag”, and “fluorescent quencher”, and quencher means molecules which are like those used in molecular beacon laboratory assays. Examples of fluorescent tags include 6-FAM (carboxylfluorescein), JOE, TET, HEX, and examples of quenchers include black-hole quenchers, DABCYL. These tags may also be referred to as “optical tags” more generally, as there are multiple types of optical emission beyond fluorescence such as phosphorescence, and because other optical properties such as optical absorbance magnitude or peak wavelength for optical absorption can also be measurable aspects of the tags.
As used herein, the term “folded aptamer” means an aptamer that along its length associates with itself in one or more locations creating a three-dimensional structure for the aptamer that is distinct from an “unfolded aptamer” that is a freely floating and oscillating strand of aptamer. Aptamers can also be partially folded or partially unfolded in structure or in time spent in the folded vs. unfolded states. Multiple folding configurations are also possible.
As used herein, the term “analyte” means any solute in a solution or fluid which can be measured using a sensor. Analytes can be small molecules, proteins, peptides, electrolytes, acids, bases, antibodies, molecules with small molecules bound to them, DNA, RNA, drugs, chemicals, pollutants, or other solutes in a solution or fluid.
As used herein, the term “membrane” means a polymer film, plug of hydrogel, liquid-infused film, tiny pore, or other suitable material which is permiselective to transport of a solute through the membrane by solute parameters such as size, charge state, hydrophobicity, physical structure, or other solute parameters than can enable permiselectivity. For example a dialysis membrane is permselective by passing small solutes but not large solutes such as proteins. Membranes as understood herein need not be multiporous, for example a nanotube or nanopore can act as a permiselective filter and is therefore considered part of a membrane as understood for the present invention. Permiselectivity can scale with the analyte, for example a membrane with a molecular weight cut-off of 50 kDa could be used to measure a 20-30 kDa protein but could still keep out cellular or other large content (globulins, fibrogen, etc.) and retain in aptamer that adequately large or physically structured such that permeability through the membrane is slow or nil.
As used herein, the term “sample fluid” means any solution or fluid that contains at least one analyte to be measured.
As used herein, the term “sensor fluid” means a solution or fluid that differs from a sample solution by at least one property, and through which the sensor solution and the sample solution are therefore separated but are in fluidic connection through at least one pathway such as a membrane. The sensor solution comprises at least one aptamer as a solute.
As used herein, the term “reservoir fluid” means a solution or fluid that differs from a sample solution by at least one property, and through which the sensor solution and the reservoir solution are in fluidic connection through at least one pathway such as a membrane or a pin-hole connection. A reservoir fluid may have multiple function in a device, for example, by introducing a solute continuously or as needed by diffusion equilibrium into the sensor fluid, or for example removing unwanted solutes from a sensor fluid and acting as a “waste removal element”.
As used herein, a “device” comprises at least one sensor based on at least one aptamer, at least one sensor solution, and at least one sample solution. Devices can sense multiple samples and be in multiple configurations such as a device to measure a pin-prick of blood, or a microneedle or in-dwelling sensor needle to measure interstitial fluid, or a device to measure saliva, tears, sweat, or urine sensor, or a device to measure water pollutants or food processing solutes, or other devices which measure at least one analyte found in a sample solution.
One or more specific embodiments of the present invention will be described below. In an effort to provide a concise description of these embodiments, all features of an actual implementation may not be described in the specification. It should be appreciated that in the development of any such actual implementation, as in any engineering or design project, numerous implementation-specific decisions must be made to achieve the developers' specific goals, such as compliance with system-related and business-related constraints, which may vary from one implementation to another. Moreover, it should be appreciated that such a development effort might be complex and time consuming, but would nevertheless be a routine undertaking of design, fabrication, and manufacture for those of ordinary skill having the benefit of this disclosure.
Certain embodiments of the disclosed invention show sensors as simple individual elements. It is understood that many sensors require two or more electrodes, reference electrodes, or additional supporting technology or features which are not captured in the description herein. Sensors measure a characteristic of an analyte. Sensors are preferably electrical in nature, but may also include optical, chemical, mechanical, or other known biosensing mechanisms. Sensors can be in duplicate, triplicate, or more, to provide improved data and readings. Sensors may provide continuous or discrete data and/or readings. Certain embodiments of the disclosed invention show sub-components of what would be sensing devices with more sub-components needed for use of the device in various applications, which are known (e.g., a battery, antenna, adhesive), and for purposes of brevity and focus on inventive aspects, such components may not be explicitly shown in the diagrams or described in the embodiments of the disclosed invention. All ranges of parameters disclosed herein include the endpoints of the ranges.
With reference to
The sensor fluid 18 contains a plurality of aptamers that are configured to specifically bind to at least one analyte 190 (shown in
In practice, light emission from optical source 120 will excite the fluorescent tags 170 on the aptamers. The fluorescence from the optical source 120 is dependent on how much analyte 190 binds to the aptamers. As a result of additional analyte 190 binding to the aptamers, the availability of the quencher 172 to suppress fluorescence from the fluorescent tag 170 is changed. The device 100 relies on diffusion of analyte 190 to/from the sample fluid 14 to the aptamers located in the sensor fluid 18. As shown in
With reference to
As with the embodiment shown in
Turning now to
As a non-limiting example, a typical optical aptamer probe is 25 nucleotides long. A portion of the 25 nucleotides, for example 15 nucleotides, are complementary to or have a strong binding affinity for the analyte target and do not base pair with one another, while the five nucleotides at each terminus are complementary to each other rather than having strong affinity to the target analyte. Accordingly, the aptamer is configured to bond with a target analyte 190, specifically at the portion of the aptamer that has a strong binding affinity for the target analyte 190. In response to the aptamer being bound to the target analyte 190, a distance between the fluorescent tag 170 and the quencher 172 increases, resulting in an increase in fluorescence to be detected by the optical detector 122 (shown in
With reference to
Referring to
In addition, there are several other parameters that may be measured by the optical detector 122 other than fluorescence, yet the device 100, 200 may still operate as an optical sensor. For example, alternatively or in addition to fluorescence, to enable robust sensing in the presence of background fluorescence, fluorescence lifetime (fluorescence intensity vs. time), can instead be sensed, which as shown in
Furthermore, the environment surrounding the optical source 120, the optical detector 122, the fluorescent tag 170 or the quencher 172 could assist in the operation of detecting a parameter in the device 100, 200. For example, one or more surfaces of either the membrane 136 or the substrate 110, can be optically reflective to confine excitation and emission light from the optical source 120 or the fluorescent tag 170 to inside the device 100 and increase a signal-to-noise ratio of optical detection. Particularly, the membrane 136 could be a track-etch membrane coated with aluminum, or a 3M Vikuity ESR reflector with laser milled holes filled with a dense agar hydrogel, either approach providing >50% and ideally >90% reflectance.
With reference to
As a nonlimiting example of that shown in
As a geometrical example, consider a membrane 536 with 0.2 cm2 area and 10% porosity to the analyte, and a diffusion restrictive feature 535 that is a pinhole in materials 510 and 550 0.001 cm2 in area and 0.001 cm in length. The mass transport for a small analyte through the membrane will be equivalent to 0.02 cm2 area and the mass transport through the feature 535 0.001 cm2, which is 20× different, satisfying the above stated criteria for design as shown in
With further reference to
As an additional example, consider phenylalanine and a ˜90 nm thick epoxy membrane 536 with an effective diffusion coefficient divided by membrane 536 thickness of Deff/Δx of between about 5 m s−1×10−3 and 0.005 m s−1×10−3, as taught by Rodler et al. in Freestanding ultrathin films for separation of small molecules in an aqueous environment, Journal of Biotechnology, Volume 288, Dec. 20, 2018, pages 48-54. (https://doi.org/10.1016/j.jbiotec.2018.10.002). The thickness or porosity of the membrane 536 can be adjusted easily. Accordingly, the present invention may benefit from a membrane 536 that has a Deff/Δx of, in one embodiment, at least 5 m s−1×10−3. In another embodiment, the Deff/Δx is at least 0.5 m s−1×10−3. In yet another embodiment, the Deff/Δx is at least 0.05 m s−1×10−3. In another embodiment, the Deff/Δx is at least 0.005 m s−1×10−3. Membranes 536 of the present invention are, in one embodiment, less than about 100 nm thick. In another embodiment, membranes of the present invention are less than 1 μm thick. In yet another embodiment, membranes of the present invention are less than 10 μm thick. In another embodiment, membranes of the present invention are less than 100 μm thick. A membrane 536 with a well-designed Deff/Δx of at least 5 m s−1×10−3 and thickness of sensor fluid 18 of ˜1-10 μm, can enable a device on/off time for the sensor to measure 90% of the sample fluid concentration in at least <15 min.
Additionally, in some cases, the analyte molecular weight will become larger or be too large to permeate the membrane 536, and the aptamer might permeate the membrane 536 due to its molecular weight or due to a stranded geometry that allows it to navigate through a membrane similar to a rope being pulled or pushed through a screen (if the rope were balled up, it could not be pushed through the screen). Therefore, alternate methods of isolating the aptamer from sample fluid 14 are needed in some cases. One important factor is the retention % vs. molecular weight, (see the graph for a membrane 536 as illustrated in
Further, as taught in other embodiments, while some aptamer may be continually lost from the sensor fluid, fresh aptamer can diffuse in from an adjacent reservoir to replenish lost aptamer. This reservoir is shown in
Such an approach could allow for protein sensing. For example, assume a sensor fluid 18 volume of 100 nL, and a membrane 536 that retains 90% of the aptamer over 6 hours, and which can allow a protein such as luteinizing hormone to diffuse into the sensor fluid 18 and achieve 90% of sample fluid 14 concentration of the hormone within 12 hrs. This would allow a device 500 to sufficiently measure luteinizing hormone for fertility monitoring applications. Now, if the reservoir including reservoir fluid 17 with aptamer had a volume of 200 μL, then it could lose 10% of its aptamer before a sensor signal would be impacted by 10%. If the device 500 is losing aptamer through the membrane 536 at a rate of, for example, 10% of aptamer every 6 hours in the 100 nL volume including sensor fluid 18, then with the 200 μL reservoir including reservoir fluid 17, the device 500 could last 2000× longer or 12,000 hours or >16 months, more than long enough for creating an implantable device 500. Therefore, depending on the volume of the reservoir including reservoir fluid 17 and scaling of other device 500 dimensions and membrane 536 porosity, the present invention can retain 90% of the initial aptamer concentration in the sensor fluid 18 for at least >16 months, >8 months, >4 months, >2 months, >1 month, >2 weeks or >1 week.
Further, and as will now be described in greater detail, there is no major penalty if the aptamer is designed such that one end of the aptamer is inactive and increases the total molecular weight of the aptamer by at least 50%. For example, in some embodiments, the aptamer includes an active end configured to bind to the analyte and which has the redox tag. In some embodiments, the aptamer may include a longer inactive end configured to provide molecular weight or size to the aptamer and/or configured to reduce aptamer permeation through the membrane 536. The longer inactive end may be configured to be rigid or have at least one permanent fold, wherein the rigid aptamer or aptamer including a permanent fold is dimensionally larger than a non-rigid aptamer or aptamer not including a permanent fold. In one embodiment, the molecular weight of such aptamers is at least >15 kDa. In another embodiment, the molecular weight of such aptamers is at least >30 kDa. In yet another embodiment, the molecular weight of such aptamers is at least >60 kDa. In one embodiment, the molecular weight of such aptamers is at least >120 kDa. For example, that active end aptamer could have a molecular weight of at least <20, <10, or <5 kDa, and the inactive end of the aptamer may be configured to be folded and therefore configured to increase the total size and molecular weight of the aptamer.
In additional embodiments, aptamers may be attached to other materials, or to nanoparticles, to also help isolate them from the sample fluid. For example, an aptamer could be attached to a polyethylene glycol polymer, the polyethylene glycol polymer may have a molecular weight of about 300 kDa, which can be referred to as a ‘particle’. Particles could be other polymers, metal such as gold, carbon, or iron-oxide and can be, in different embodiments, at least >1 nm, >3 nm, >10 nm, >30 nm, or >100 nm in diameter and still stably dispersed in solution as is known using one or more methods like those used in the art of pigment and nanodispersions. Aptamers can be bound to iron nanoparticles using, as a non-limiting example, dibromomaleimide (DBM)-tennination, and bound to gold nanoparticles using thiol termination. With use of magnetic nanoparticles such as iron-oxide, the aptamer isolation element may also be a magnet that retains the nanoparticles near the membrane with or without use of a membrane, and in this example the aptamer isolation element is a magnet. This approach could allow the present invention to measure a protein analyte, for example a 30 kDa protein with an average diameter of <5 nm.
Consider an example that teaches the impact of device parameters on device lag time. Assume a device that operates with a sample fluid that is interstitial fluid and where ˜1 μM of fluorescently tagged aptamer is used to provide a safe margin on tag signal strength vs. background fluorescence interferents. If the distance between the membrane and electrode was 5 μm, then for cortisol at 10 nM and 1 μM aptamer the ‘equivalent’ volume of sensor fluid is 100× greater or 500 μm thick from a lag time perspective. Next, assume a membrane that is 10% porous to cortisol, for this configuration, the cortisol can diffuse into the sensor fluid and reach 90% of its concentration in the sample fluid in less than 20 minutes. Next, utilize a membrane that is 1.66% or 50% porous to cortisol, and the lag time becomes 60 min or as little as 4 min, respectively. Aptamer concentration can be increased or decreased to adjust this lag time, the distance between the membrane and electrode and/or substrate can be modified to adjust this lag time by adjusting the sensor fluid volume, and for different analytes a higher or lower analyte concentration will also adjust this lag time (e.g., cortisol at 1 nM will have 10× greater lag time while cortisol at 100 nM would have 10× lesser lag time. Therefore generally, the present invention can enable devices with lag times to reach 90% of sensor response that are less than at least one of 180 min, 60 min, 20 min, 5 min, 2 min. The challenges with reduced sample volumes for optical detection include shorter optical detection path lengths, and therefore detection volumes could instead be primarily the space in between elements 120, 122, as illustrated in
Although not described in detail herein, other steps which are readily interpreted from or incorporated along with the disclosed embodiments shall be included as part of the invention. The embodiments that have been described herein provide specific examples to portray inventive elements, but will not necessarily cover all possible embodiments commonly known to those skilled in the art.
This application claims the benefit of the filing date of U.S. patent application Ser. No. 63/082,834, filed on Sep. 24, 2020; claims the benefit of the filing date of U.S. patent application Ser. No. 63/082,999, filed on Sep. 24, 2020; claims the benefit of the filing date of U.S. patent application Ser. No. 63/083,029, filed on Sep. 24, 2020; claims the benefit of the filing date of U.S. patent application Ser. No. 63/085,484, filed on Sep. 30, 2020; claims the benefit of the filing date of U.S. patent application Ser. No. 63/122,071, filed on Dec. 7, 2020; claims the benefit of the filing date of U.S. patent application Ser. No. 63/122,076, filed on Dec. 7, 2020; claims the benefit of the filing date of U.S. patent application Ser. No. 63/136,262, filed on Jan. 12, 2021; claims the benefit of the filing date of U.S. patent application Ser. No. 63/150,667, filed on Feb. 18, 2021; claims the benefit of the filing date of U.S. patent application Ser. No. 63/150,677, filed on Feb. 18, 2021; claims the benefit of the filing date of U.S. patent application Ser. No. 63/150,712, filed on Feb. 18, 2021; claims the benefit of the filing date of U.S. patent application Ser. No. 63/150,856, filed on Feb. 18, 2021; claims the benefit of the filing date of U.S. patent application Ser. No. 63/150,865, filed on Feb. 18, 2021; claims the benefit of the filing date of U.S. patent application Ser. No. 63/150,894, filed on Feb. 18, 2021; claims the benefit of the filing date of U.S. patent application Ser. No. 63/150,944, filed on Feb. 18, 2021; claims the benefit of the filing date of U.S. patent application Ser. No. 63/150,953, filed on Feb. 18, 2021; claims the benefit of the filing date of U.S. patent application Ser. No. 63/150,986, filed on Feb. 18, 2021; and claims the benefit of the filing date of U.S. patent application Ser. No. 63/197,674, filed on Jun. 7, 2021, the disclosures of each of which are incorporated by reference herein in their entireties.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US2021/051967 | 9/24/2021 | WO |
Number | Date | Country | |
---|---|---|---|
63197674 | Jun 2021 | US | |
63150667 | Feb 2021 | US | |
63150677 | Feb 2021 | US | |
63150712 | Feb 2021 | US | |
63150856 | Feb 2021 | US | |
63150865 | Feb 2021 | US | |
63150894 | Feb 2021 | US | |
63150944 | Feb 2021 | US | |
63150153 | Feb 2021 | US | |
63150986 | Feb 2021 | US | |
63136262 | Jan 2021 | US | |
63122071 | Dec 2020 | US | |
63122076 | Dec 2020 | US | |
63085484 | Sep 2020 | US | |
63082834 | Sep 2020 | US | |
63082999 | Sep 2020 | US | |
63083029 | Sep 2020 | US |